Note 15 - Segment and Geographic Information

9 Months Ended

Feb. 28, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

15.  SEGMENT AND GEOGRAPHIC INFORMATION

Through February 2013, the Company was organized by geographic area and reported three operating segments: the United States, Europe and Other. In March 2013, after the acquisition of the LIFECODES business, the Company reorganized its operating structure, and reevaluated its reportable operating segments accordingly. The Company determines operating segments in accordance with its internal operating structure, which is organized based upon product groups. Each segment is separately managed and is evaluated primarily upon operating results. The Company has two operating segments, the Transfusion segment and the Transplant & Molecular segment, which have been aggregated into one reportable segment. The financial information provided below has been recast to reflect the Company’s new segment structure for each period presented.

The Company manufactures and markets a complete line of diagnostics products and automated systems used primarily by hospitals, donor centers and reference laboratories in a number of tests performed to detect and identify certain properties of human blood and human tissue to ensure the most compatible match between patient and donor. These tests are performed for the purpose of blood transfusion, pre-transplant human leukocyte antigen (HLA) typing and screening processes as well as post-transplant patient monitoring to aid in the identification of graft rejection.

The Company operates in various geographies. These geographic markets are comprised of the United States, Europe, Canada and other international markets. Major international markets, other than Europe and Canada, include Japan, Brazil, Russia, India, China, Turkey, the Middle East and Africa. The Company’s products are marketed globally, both directly to the end user and through established distributors.

Accounting policies for segments are the same as those described in the summary of significant accounting policies.

The following is a summary of the Company’s segment data (in thousands):

	Three Months Ended				Nine Months Ended
	February 28				February 28
	2014		2013		2014		2013
Net sales by product group:
Transfusion	$	77,381		84,494		245,930		248,426
Transplant & Molecular		13,598		1,698		41,296		4,976
Total	$	90,979		86,192		287,226		253,402

Following is a summary of enterprise-wide information (in thousands):

	Three Months Ended
	February 28
	2014		2013
Net sales to customers by geography are as follows:
United States	$	55,240		57,690
Europe (A)		19,964		14,895
Canada		4,429		5,044
Other		11,346		8,563
Total	$	90,979		86,192

	Nine Months Ended
	February 28
	2014		2013
Net sales to customers by geography are as follows:
United States	$	177,722		167,944
Europe (A)		57,188		44,933
Canada		14,044		14,618
Other		38,272		25,907
Total	$	287,226		253,402

Net sales are attributed to individual countries based on the customer’s country of origin at the time of the sale and where the Company has an operating entity.

	As of
	February 28, 2014		May 31, 2013
Long-lived tangible assets by geography:
United States	$	54,646		57,184
Europe (B)		15,155		13,399
Canada		4,321		4,511
Other (C)		1,840		1,287
Total	$	75,962		76,381

	As of
	February 28, 2014		May 31, 2013
Concentration of net assets by geography:
United States	$	467,084		485,968
Europe		123,987		114,740
Canada		31,404		32,910
Other (C)		12,781		11,088
Total	$	635,256		644,706

(A) – Net sales to any individual country within Europe were not material to the Company’s consolidated net sales.

(B) – Long-lived assets located in any individual country within Europe were not material to the Company's consolidated long-lived assets.

(C) – Primarily Japan and India.

Sales to an individual customer did not exceed more than 10% of our net sales during the three months and nine months ended February 28, 2014, or February 28, 2013.